Lerodalcibep (Lerochol)
Lerodalcibep (Lerochol) is a once-monthly injected PCSK9-binding protein. Its pivotal trials showed LDL reductions of about 50–59% versus placebo on background treatment, depending on the population and follow-up. Study results
How much does lerodalcibep lower LDL cholesterol?
Lerodalcibep 300 mg monthly lowered LDL cholesterol by 55% and 50% versus placebo at week 52 in two trials, and by 59% at week 24 in a trial of heterozygous familial hypercholesterolemia. Read the evidence.
| Dose and treatment context | LDL result |
|---|---|
| 300 mg monthly; trial 1, week 52 | 55% vs. placebo |
| 300 mg monthly; trial 2, week 52 | 50% vs. placebo |
| 300 mg monthly; HeFH, week 24 | 59% vs. placebo |
These are separate trial populations on background treatment, not three dose levels.
Individual responses vary. LDL and ApoB measure different things; these LDL percentages should not be used as ApoB estimates. Compare ApoB-lowering treatments.
How is lerodalcibep taken?
Lerochol is given as a 300 mg injection under the skin once a month. Patients or caregivers need training before administering it. Follow the product’s storage, preparation, and missed-dose instructions. Prescribing information.
How does lerodalcibep compare with other medications?
Lerochol offers a monthly PCSK9 option alongside Repatha and Praluent. Its protein structure differs from an antibody, and LDL results should not be interpreted as a head-to-head demonstration of superiority.
Which medications can be combined with lerodalcibep?
This treatment can be used on top of a statin, often with Ezetimibe. Combining multiple PCSK9-directed drugs is not a routine strategy; switching agents is different from taking them together. The choice depends on the needed LDL reduction, dosing preference, and insurance requirements.
How much does lerodalcibep cost?
The manufacturer advertises a one-month supply of Lerochol for $199 through its direct-to-patient program. Program terms and eligibility apply. Offers checked October 6, 2026; availability and eligibility can change.
Lerochol direct-to-patient program
The manufacturer advertises a one-month supply of Lerochol for $199 through its direct-to-patient program. Program terms and eligibility apply.
GoodRx
Compare available pharmacy cash prices and coupons for the exact product and quantity. A pharmacy price may exclude administration charges and may differ from a manufacturer program.
Compare the cash price with your plan’s out-of-pocket quote for the same strength and quantity. Coupon purchases may not count toward your insurance deductible.
Does insurance cover lerodalcibep?
Coverage for lerodalcibep varies by plan and formulation. These named formularies and medical policies were checked October 6, 2026; your plan’s rules and cost sharing may differ.
| Insurer | Coverage policy |
|---|---|
| UnitedHealthcare | No listing for lerodalcibep was located in this named pharmacy formulary. This does not establish a denial; ask the plan about its current drug list, exceptions, and medical-benefit coverage. Commercial PDL, September 2026. |
| Aetna | Lerochol is listed as nonformulary; coverage would require a plan-specific exception or alternative. Advanced Control, October 2026. |
| Cigna | No listing for lerodalcibep was located in Cigna’s current California pharmacy formulary. Ask about a formulary exception and any separate clinical policy; absence alone does not establish a denial. California Standard 4-Tier (DMHC), July 2026. |
| Anthem | No listing for lerodalcibep was located in this named pharmacy formulary. This does not establish a denial; ask the plan about its current drug list, exceptions, and medical-benefit coverage. California Individual Select, October 2026. |
| Blue Shield of California | No listing for lerodalcibep was located in this named pharmacy formulary. This does not establish a denial; ask the plan about its current drug list, exceptions, and medical-benefit coverage. Standard Formulary. |
| BCBS of Texas | No listing for lerodalcibep was located in this named pharmacy formulary. This does not establish a denial; ask the plan about its current drug list, exceptions, and medical-benefit coverage. Performance Annual, 2026. |
What are the side effects of lerodalcibep?
Injection-site reactions are an important adverse effect: one trial reported them in 12% of treated patients versus 5% with placebo. Upper respiratory symptoms and peripheral edema were also reported. Review any persistent reaction or symptoms of allergy. Full safety information.
Does lerodalcibep reduce heart attacks or strokes?
The cited pivotal trials establish LDL lowering. They do not provide a dedicated estimate of how much lerodalcibep reduces heart attacks or strokes; cardiovascular outcome results from other PCSK9 drugs should not be presented as Lerochol-specific results. Read the supporting evidence.
Is lerodalcibep right for you?
Empirical helps connect your lab results, cardiovascular risk, and treatment options.
Explore heart health care